Syntara has announced the first patient has been dosed in its randomised double-blind placebo controlled Phase 2 study of the Syntara drug discovery PXS-4728 studying patients with isolated Rapid Eye Movement Sleep Behaviour Disorder (iRBD) who are at risk of Parkinson’s disease. The study will examine whether targeting inflammation in the brain of people with iRBD might provide a viable neuroprotective strategy to prevent Parkinson’s and other neurogenerative diseases. The multi-national trial is majority funded by the Parkinson’s Virtual Biotech, the international drug discovery and development program founded by Parkinson’s UK. Read more here.